Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04071457
Title S1803, Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Southwest Oncology Group
Age Groups: adult | senior
Covered Countries USA | CAN

No variant requirements are available.